They show better efficacy in in vivo models than other CD19-targeted CART therapy products on the market. Genechem’s CD19-CART has also shown improved clinical results and reduced immune ...

an allogeneic CAR T-cell therapy targeting CD19/CD20, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2219 is developed based on CARsgen's THANK-u Plus ...

In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...

SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies ...

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics, a leading cell and gene therapy statrtup backed by entrepreneur Kiran Mazumdar-Shaw, has unveiled Qartemi, the ...

an allogeneic CAR T-cell therapy, targeting CD19/CD20. The trial will evaluate KJ-C2219 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). KJ-C2219 is developed ...

This universal expression and specificity for a single cell lineage have rendered CD19 an appealing target for antibody-based therapy, such as ADCs, bispecific antibodies, Fc-engineered antibodies ...

31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid ...

Caribou Biosciences (NASDAQ:CRBU) stock tumbled 30% Monday amid the release of Phase 1 data from its ANTLER study for the company’s CART-T ... any prior CD19-targeted therapy in a proof-of ...